Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Differentiated thyroid epithelioma]

M Schlumberger1, E Baudin, J P Travagli

  • 1Service de médecine nucléaire, Institut Gustave-Roussy, Villejuif.

La Revue Du Praticien
|December 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics, management, and outcomes of patients with VIPoma-A retrospective analysis of the ENETS database.

Journal of neuroendocrinology·2026
Same author

Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial.

ESMO open·2025
Same author

Time-domain braiding of anyons.

Science (New York, N.Y.)·2025
Same author

Proof of concept and design of an externally controlled trial for patients with gastro-enteropancreatic neuroendocrine carcinomas based on the randomized phase II BEVANEC trial.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Time-resolved sensing of electromagnetic fields with single-electron interferometry.

Nature nanotechnology·2025
Same author

Neuroendocrine neoplasms of head and neck, genitourinary and gynaecological systems, unknown primaries, parathyroid carcinomas and intrathyroid thymic neoplasms: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

ESMO open·2024
Same journal

[Prolonged fever].

La Revue du praticien·2026
Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026
Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026
Same journal

[Patient education in heart failure].

La Revue du praticien·2026
See all related articles

Differentiated thyroid carcinoma has a favorable long-term prognosis, influenced by age and histology. Treatment involves surgery, radioactive iodine (131I) therapy, and L-thyroxine, with early relapse detection via thyroglobulin tests and 131I scans.

Area of Science:

  • Endocrinology
  • Oncology
  • Surgical Oncology

Context:

  • Differentiated thyroid carcinoma (DTC) management requires a nuanced approach.
  • Prognosis is significantly influenced by patient age and tumor histology.
  • Optimal treatment strategies balance surgical intervention with adjuvant therapies.

Purpose:

  • To outline the established treatment protocols for differentiated thyroid carcinoma.
  • To emphasize the importance of prognostic factors in guiding therapeutic decisions.
  • To highlight methods for early detection of tumor recurrence.

Summary:

  • Initial surgical management for DTC varies: loboisthmusectomy for small, intrathyroidal tumors in low-risk patients, and total thyroidectomy for others.
  • All patients undergo routine paratracheal and supraclavicular lymph node dissection and receive L-thyroxine therapy.

Related Experiment Videos

  • Early identification of relapses is crucial, facilitated by serum thyroglobulin monitoring and radioactive iodine (131I) whole-body scans.

    • Impact:

    • Establishes a framework for effective DTC management, improving patient outcomes.
    • Guides clinical decision-making by integrating prognostic factors into treatment planning.
    • Promotes timely intervention for recurrent disease, enhancing survival rates.